



Erratum

Erratum to ‘Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis’ [Eur J Cancer 149 (2021) 134–152]



Francesco Schettini ^{a,b,c,*}, Fabiola Giudici ^d, Ottavia Bernocchi ^e,
 Marianna Sirico ^f, Silvia P. Corona ^e, Mario Giuliano ^a,
 Mariavittoria Locci ^g, Ida Paris ^h, Giovanni Scambia ^{h,i},
 Sabino De Placido ^a, Pasquale Rescigno ^j, Aleix Prat ^{b,c,k},
 Giuseppe Curigliano ^l, Daniele Generali ^{e,f}

^a Department of Clinical Medicine and Surgery, University of Naples ‘Federico II’, Naples, Italy

^b Translational Genomics and Targeted Therapies in Solid Tumours, IDIBAPS, Barcelona, Spain

^c SOLTI Breast Cancer Research Group, Barcelona, Spain

^d Unit of Biostatistics, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy

^e Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy

^f Breast Cancer Unit, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy

^g Department of Neuroscience, Reproductive Sciences and Dentistry, University of Naples Federico II, Naples, Italy

^h Department of Woman and Child Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy

ⁱ Università Cattolica Del Sacro Cuore, Rome, Italy

^j Interdisciplinary Group for Translational Research and Clinical Trials (GIRT-Uro), Candiolo Cancer Institute, FPOIRCCS, Candiolo, Italy

^k Department of Oncology, Hospital Clinic of Barcelona, Barcelona, Spain

^l Istituto Europeo di Oncologia, IRCCS ed Università di Milano, Milano, Italy

The publisher regrets that errors were made regarding the named trial PRIMA in section 4.4. ‘Results based on mutational status’.

The sentence ‘Intriguingly, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) trial in ovarian cancer was able to identify a PFS improvement with niraparib monotherapy in

HRR-proficient MOC [31].’ should have appeared as follows

‘Intriguingly, the PRIMA trial in ovarian cancer was able to identify a PFS improvement with niraparib monotherapy in HRR-proficient MOC [31].’

The publisher would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.ejca.2021.02.035>.

* Corresponding author: Translational Genomics and Targeted Therapies in Solid Tumours, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Carrer de Villaróel 170, Barcelona, 08036, Spain.

E-mail address: schettini@clinic.cat (F. Schettini).

<https://doi.org/10.1016/j.ejca.2021.06.001>

0959-8049/© 2021 Elsevier Ltd. All rights reserved.